1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Ildong Holdings Co., Ltd.

Ildong Holdings Co., Ltd.

000230.KS
Ildong Holdings Co., Ltd.KR flagKorea Exchange
6,120.00
KRW
+60.00
- -
70.63BMarket Cap
Ildong Holdings Co., Ltd.
000230.KS
(Korea Exchange)

Recent

price

6,120.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
45,096.69
45,261.57
47,134.21
51,419.05
54,211.94
4,977.01
2,172.23
4,037.08
4,373.29
24,584.87
52,821.54
52,460.07
59,823.47
56,005.11
56,198.43
52,298.46
52,928.76
Revenue per Share
2,414.52
3,545.82
2,194.16
843.67
1,539.38
2,726.18
14,171.43
7.26
-345.71
-1,889.52
-1,699
-6,278
-9,064
-5,227
5,582
967
1,449.01
Basic EPS, GAAP
1,516.18
3,421.65
-3,415.67
-5,957.99
-573.27
2,176.33
239.77
-435.68
282.06
-39.15
-1,308.86
-4,718.65
-8,477.95
-6,777.2
152.13
794.01
690.33
Free Cash Flow per Basic Share
566.71
440.72
566.17
476.28
508.31
631.42
389.9
105.21
194.56
174.88
96.82
105.23
115.85
120.85
106.79
5.32
- -
Dividend per Share
24,347.92
34,344.68
35,956.06
36,388.67
37,047.82
38,900.49
28,768.99
5,125.1
-12.59
-2,090.1
79.65
-6,194.75
-14,934.19
-20,203.17
-14,646.1
-9,659.93
-9,225.01
Book Value per Share
37,865.7
38,858.28
39,984.33
38,767.31
37,999.11
37,490.02
5,621.95
16,982.62
15,216.09
13,154.15
13,433.85
3,042.69
4,400.62
5,208.16
14,679.53
23,607.35
23,632.28
Tangible Book Value per Share
8
8
8
8
8
8
19
10
11
12
11
11
11
11
11
11
11
Basic Weighted Avg Shares
347,160
348,468
362,781
395,231
417,517
38,301
40,771
41,071
47,050
292,221
596,469
592,375
675,540
638,448
634,655
590,890
602,057
Sales/Revenue/Turnover
8.06
11.1
3.85
6.02
3.46
-12.89
-9.16
-4.45
0.04
-8.85
-1.54
-13.79
-14.55
-12.46
-0.63
2.56
3.51
Operating Margin (%)
19,982
11,229
12,605
14,228
16,357
18,277
12,253
2,503
2,931
20,983
38,245
40,072
39,431
37,945
36,508
29,340
28,605
Depreciation Expense
18,587
27,299
16,888
6,485
11,856
20,979
265,988
74
-3,719
-22,459
-19,185
-70,891
-102,353
-59,587
63,038
10,926
16,482
Net Income, GAAP
25.84
21.38
- -
54.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
36.47
26.83
Effective Tax Rate (%)
5.35
7.83
4.66
1.64
2.84
54.78
652.39
0.18
-7.91
-7.69
-3.22
-11.97
-15.15
-9.33
9.93
1.85
2.74
Profit Margin (%)
116,863
108,347
91,645
101,635
92,301
98,213
30,585
-23,285
-26,780
-61,117
-49,675
-171,687
-168,807
-261,906
-101,852
-74,357
-59,502
Working Capital
39,138
13,400
21,400
64,564
67,590
75,495
30,078
60
43
26,738
46,991
82,331
43,751
42,453
110,464
6,564
6,277
LT Debt
295,000
310,172
324,416
326,605
332,950
349,981
106,838
174,057
164,946
323,840
305,608
183,340
169,100
169,902
253,998
345,580
347,825
Total Equity
4.9
7.32
- -
2.39
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.69
2.79
Return on Invested Capital (%)
6.45
9.07
- -
2.2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.49
5.24
Return on Capital (%)
10.31
12.08
6.24
2.33
4.2
7.18
63.38
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
234,958
192,952
182,457
LT Borrowings
3,890
3,769
3,647
LT Finance Leases
3,044
2,795
2,630
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
12
12
Market Capitalization
132,048
149,993
112,839

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
271,070
242,570
245,056
Cash, Cash Equivalents & STI
100,331
77,815
77,695
Accounts Receivable, Net
48,485
49,582
48,374
Inventories
101,996
102,894
105,066
Total Current Liabilities
359,656
316,927
304,558
Payables & Accruals
- -
- -
- -
ST Debt
234,958
192,952
182,457
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.72%
7.65%
36.06%
Free Cash Flow
316.16%
128.17%
422.19%
Net Income, GAAP
-359.76%
-3.27%
-82.67%
Sales/Revenue/Turnover
64.73%
0.07%
-6.9%
Total Cash Common Dividend
-7.07%
-16.68%
-95.01%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
161,856
157,741
160,746
166,341
634,655
2025
141,085
148,840
150,509
153,826
590,890
2026
148,882
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-542
66
-700
- -
5,582
2025
-422
-460.18
87.95
- -
967
2026
123.31
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
106.79
2025
- -
- -
- -
- -
5.32
2026
- -
- -
- -
- -
- -
Similar Companies
Origin Therapeutics Holdings Inc. (ORIG.CN)
Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS)
Mydecine Innovations Group Inc. (MYCO.NE)
PharmaCielo Ltd. (PCLOF)
Allergy Therapeutics plc (AGYTF)
Indoco Remedies Limited (INDOCO.NS)
Business
Ildong Holdings Co., Ltd. operates as a holding company primarily engaged in the pharmaceutical industry, headquartered in Seoul, South Korea, and founded in 1941. The company develops, manufactures, and supplies a comprehensive range of pharmaceutical products including original and generic prescription drugs, finished drugs, raw material drugs, antifungals, antivirals, anti-histamines, antineoplastic agents, blood circulation and cardiovascular drugs, central nervous system drugs, endocrine and metabolic system treatments, gastrointestinal and respiratory system products, topical preparations, and urogenital system medicines. Additionally, Ildong Holdings offers health foods, probiotics such as its Biovita lactobacillus product, multivitamins like Aronamin, medical devices, cosmetics, and wound care dressings including the Meditouch brand. It also provides contract manufacturing (CMO) services using GMP-certified facilities, focusing on antibiotics and oncology drugs. In recent major corporate developments, Ildong Holdings has restructured its business portfolio to improve management efficiency and financial stability, exemplified by the July 2025 sale of its entire stake in Ildong Bioscience to its subsidiary Ildong Pharmaceutical for approximately KRW 14.2 billion, enhancing profitability and streamlining operations with a focus on expanding its health functional foods value chain. The company also maintains strategic alliances in new drug development and has invested in R&D subsidiaries such as iLeadBMS and Idience to strengthen its drug development pipeline in areas including resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and aging. Through its subsidiaries, Ildong Holdings operates in contract manufacturing, research, and the distribution of pharmaceuticals, medical devices, health supplements, and consumer healthcare products across South Korea and export markets like Southeast Asia. Ildong Holdings is positioned in the pharmaceutical and healthcare segment with a diversified product portfolio targeting hospitals, clinics, and consumers via various distribution channels including online platforms. The company continues evolving with innovations in pharmaceuticals, supplements, cosmetics, and medical devices, supporting its long-term vision of becoming a global total healthcare company. Its recent strategic moves reflect a commitment to focusing on core pharmaceutical operations while bolstering its health functional food and biotechnology businesses for sustainable growth.